Get the Stockscreener App
5.29
0.57%
0.03
Kyverna Therapeutics Inc stock is traded at $5.29, with a volume of 226.06K.
It is up +0.57% in the last 24 hours and up +15.00% over the past month.
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
See More
Previous Close:
$5.26
Open:
$5.25
24h Volume:
226.06K
Relative Volume:
0.60
Market Cap:
$228.25M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+8.18%
1M Performance:
+15.00%
6M Performance:
-58.21%
1Y Performance:
+0.00%
1-Day Range:
$5.0102
$5.39
1-Week Range:
$4.78
$5.61
52-Week Range:
$4.40
$30.60
Kyverna Therapeutics Inc Stock (KYTX) Company Profile
Name
Kyverna Therapeutics Inc
Sector
Industry
Phone
(510) 626-8331
Address
5980 HORTON STREET, EMERYVILLE
Kyverna Therapeutics Inc Stock (KYTX) Latest News
(KYTX) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Analysts Set Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Price Target at $28.71 - Defense World
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Short Interest Up 9.7% in October - MarketBeat
(KYTX) Trading Report - Stock Traders Daily
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Purchased by Novo Holdings A S - MarketBeat
Kyverna Therapeutics to Participate in Upcoming September Invest - GuruFocus.com
Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors - cnhinews.com
Kyverna Therapeutics expands board with biotech veteran By Investing.com - Investing.com UK
Kyverna Therapeutics (KYTX): Leading Nano Cap with Promising CAR T-Cell Therapy - Insider Monkey
(KYTX) Technical Data - Stock Traders Daily
500: Something went wrong - Investing.com
JPMorgan bullish on Kyverna Therapeutics stock amid CAR-T expansion potential - Investing.com UK
7 Best Nano Cap Stocks To Invest In - Insider Monkey
The Kyverna Therapeutics Inc. (KYTX) had a good session last reading, didn’t it? - US Post News
Kyverna Therapeutics Inc. (KYTX) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Sold by Marshall Wace LLP - MarketBeat
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives $28.71 Consensus Price Target from Analysts - Defense World
Kyverna, Cabaletta started at buys by UBS on CAR T therapy potential - MSN
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives $28.71 Consensus Target Price from Analysts - MarketBeat
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Bought by Millennium Management LLC - MarketBeat
Buy rating assigned to Kyverna Therapeutics stock as analyst notes promising therapy data - Investing.com
Down rounds don’t aid post-IPO performance - BioCentury
JPMorgan Chase & Co's Strategic Acquisition in Kyverna Therapeutics Inc - GuruFocus.com
Kyverna, Cabaletta started at buys by UBS on CAR T therapy potential (NASDAQ:KYTX) - Seeking Alpha
Buy rating assigned to Kyverna Therapeutics stock as analyst notes promising therapy data By Investing.com - Investing.com South Africa
Kyverna Therapeutics (NASDAQ:KYTX) Research Coverage Started at UBS Group - MarketBeat
Kyverna Therapeutics (NASDAQ:KYTX) Lifted to Strong-Buy at RODMAN&RENSHAW - MarketBeat
Kyverna Therapeutics (NASDAQ:KYTX) Coverage Initiated by Analysts at Rodman & Renshaw - MarketBeat
Market Update: Kyverna Therapeutics Inc. (KYTX) Sees Negative Movement, Closing at 4.89 - The Dwinnex
Novo Holdings A S Acquires 1,050,000 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat
Biotech Kyverna Surges 36% in Debut After Boosting IPO Size - MSN
MBB Public Markets I LLC Acquires New Stake in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat
Deerfield Management Company L.P. Series C Acquires 520,663 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Purchased by Deerfield Management Company L.P. Series C - MarketBeat
Skandinaviska Enskilda Banken AB publ Acquires 9,385 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World
Affinity Asset Advisors LLC Buys Shares of 200,000 Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat
Affinity Asset Advisors LLC Takes $1.50 Million Position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World
Bank of New York Mellon Corp Purchases Shares of 55,790 Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Acquired by Great Point Partners LLC - Defense World
Great Point Partners LLC Increases Stock Holdings in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat
A Tale of Resilience: Kyverna Therapeutics Inc. Amid Stock Market Turbulence - The InvestChronicle
XTX Topco Ltd Acquires Shares of 83,286 Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World
ECTRIMS 2024: Driving a fast CAR on the MS road and beyond - BioWorld Online
Market Momentum Report: Kyverna Therapeutics Inc. (KYTX)’s Negative Close at 6.39 - The Dwinnex
2 Kite vets fly over to Kyverna Therapeutics—Chutes & Ladders - Fierce Biotech
Kyverna Therapeutics (NASDAQ:KYTX) Rating Reiterated by HC Wainwright - MarketBeat
Kyverna Therapeutics stock maintains Neutral rating from H.C. Wainwright - Investing.com
Kyverna Therapeutics’ (KYTX) Neutral Rating Reiterated at HC Wainwright - Defense World
The Escalator: Imre, Kyverna Therapeutics, The Bloc and more - MM+M Online
Kyverna Therapeutics Inc Stock (KYTX) Financials Data
There is no financial data for Kyverna Therapeutics Inc (KYTX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Kyverna Therapeutics Inc Stock (KYTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Jones Ryan Alexander | Chief Financial Officer |
May 28 '24 |
Option Exercise |
0.73 |
18,016 |
13,152 |
43,950 |
| Vida Ventures, LLC | 10% Owner |
Feb 12 '24 |
Buy |
22.00 |
253,136 |
5,568,992 |
252,553 |
| Bain Capital Life Sciences Inv | 10% Owner |
Feb 12 '24 |
Buy |
22.00 |
450,000 |
9,900,000 |
3,163,868 |
| GILEAD SCIENCES, INC. | 10% Owner |
Feb 12 '24 |
Buy |
22.00 |
910,000 |
20,020,000 |
4,126,119 |
| Northpond Ventures III GP, LLC | Former 10% Owner |
Feb 12 '24 |
Buy |
22.00 |
450,000 |
9,900,000 |
450,000 |
1.47%
6.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):